U.S. markets close in 2 hours 2 minutes
  • S&P 500

    3,669.36
    +83.74 (+2.34%)
     
  • Dow 30

    29,430.22
    +704.71 (+2.45%)
     
  • Nasdaq

    10,785.60
    +209.98 (+1.99%)
     
  • Russell 2000

    1,705.61
    +40.90 (+2.46%)
     
  • Crude Oil

    83.23
    +3.74 (+4.71%)
     
  • Gold

    1,705.60
    +33.60 (+2.01%)
     
  • Silver

    20.70
    +1.67 (+8.75%)
     
  • EUR/USD

    0.9797
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    3.6410
    -0.1630 (-4.28%)
     
  • GBP/USD

    1.1270
    +0.0104 (+0.93%)
     
  • USD/JPY

    144.6340
    -0.0950 (-0.07%)
     
  • BTC-USD

    19,544.86
    +332.41 (+1.73%)
     
  • CMC Crypto 200

    444.67
    +9.32 (+2.14%)
     
  • FTSE 100

    6,908.76
    +14.95 (+0.22%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease

·5 min read
FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease

The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.